03782oam 2200685I 450 991078924410332120230803202142.00-429-16933-71-4665-9387-310.1201/b16749 (CKB)3710000000099004(EBL)1408064(SSID)ssj0001181236(PQKBManifestationID)11639740(PQKBTitleCode)TC0001181236(PQKBWorkID)11143189(PQKB)11074665(OCoLC)880460508(MiAaPQ)EBC1408064(OCoLC)876288586(EXLCZ)99371000000009900420180331h20142014 uy 0engur|n|---|||||txtccrClinical and statistical considerations in personalized medicine /edited by Claudio Carini, Pfizer, Cambridge, Massachusetts, USA, Sandeep M. Menon, Pfizer, Cambridge, Massachusetts, USA, Mark Chang, AMAG Pharmaceuticals, Incorporated Waltham, MassachBoca Raton :CRC Press,[2014]©20141 online resource (368 p.)Chapman and Hall/CRC Biostatistics SeriesDescription based upon print version of record.1-306-86777-0 1-4665-9386-5 Includes bibliographical references.Front Cover; Contents; Preface; Editors; Contributors; Chapter 1: Biomarkers for Drug Development: The Time Is Now!; Chapter 2: RNAi Screens: Triumphs and Tribulations; Chapter 3: Current Advances in Epigenetics; Chapter 4: Biomarkers and Precision Medicine: The Case of Rare Diseases; Chapter 5: Biomarker-Informed Adaptive Design; Chapter 6: Fitting the Dose: Adaptive Staggered Dose Design; Chapter 7: Evidence-Based Adaptive Statistical Decision and Design Strategies for; Chapter 8: Biomarker Identification in Clinical Trials; Chapter 9: Multiplicity in PharmacogenomicsChapter 10: Patient-Reported Outcomes in Personalized MedicineChapter 11: Regulatory Issues in Use of Biomarkers in Drug Development; Back CoverPersonalized medicine has the potential to change the way we think about, identify, and manage health problems. In the pharmaceutical industry, it is already having an exciting impact on both clinical research and patient care. This impact will continue to grow as our understanding and technologies improve. With contributions from well-known industry leaders in clinical development, this book covers the practical aspects of personalized medicine, focusing on issues that have direct application in the industry. Topics include designs for targeted therapy, adaptive designs, evidence-based adaptive statistical decisions, and design strategies for maximizing the efficiency of clinical oncology--Provided by publisher.Chapman & Hall/CRC biostatistics series (Unnumbered)PharmacogeneticsMathematical modelsPharmacogeneticsStatistical methodsPharmacogenomicsMathematical modelsPharmacogenomicsStatistical methodsPharmacogeneticsMathematical models.PharmacogeneticsStatistical methods.PharmacogenomicsMathematical models.PharmacogenomicsStatistical methods.615.7072/7615.70727MAT029000MED045000MED071000bisacshCarini ClaudioMenon Sandeep M.Chang MarkFlBoTFGFlBoTFGBOOK9910789244103321Clinical and statistical considerations in personalized medicine3699001UNINA